about
Real-world study of everolimus in advanced progressive neuroendocrine tumors.Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.Optimal treatment of Zollinger-Ellison syndrome and related conditions in elderly patients.Factors related to long-term survival in patients affected by well-differentiated endocrine tumors of the pancreas.Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreasPET/CT with 68Gallium-DOTA-peptides in NET: an overview.⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.Sporadic Small (≤20 mm) Nonfunctioning Pancreatic Neuroendocrine Neoplasm: is the Risk of Malignancy Negligible When Adopting a More Conservative Strategy? A Systematic Review and Meta-analysis.Prognostic Value of 68Ga-DOTANOC PET/CT SUVmax in Patients with Neuroendocrine Tumors of the Pancreas.Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study.Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study.A meal stimulation test in the diagnosis of pancreatic endocrine tumors in multiple endocrine neoplasia type 1.Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid.Endocrine tumors of the ileum: factors correlated with survival.Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series.Advanced digestive neuroendocrine tumors: metastatic pattern is an independent factor affecting clinical outcome.Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence.Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.Standardized uptake values of (68)Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors.Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors.Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs.Warm water or oil-assisted colonoscopy: toward simpler examinations?Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study.Risk factors of type 1 gastric neuroendocrine neoplasia in patients with chronic atrophic gastritis. A retrospective, multicentre study.Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study.Is surgery the best treatment for sporadic small (≤2 cm) non-functioning pancreatic neuroendocrine tumours? A single centre experience.Efficacy and cost-effectiveness of immediate surgery versus a wait-and-see strategy for sporadic nonfunctioning T1 pancreatic endocrine neoplasms.Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation.Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis.Patient-reported outcomes in patients with endocrine tumors of the ileum.Evaluation of patient-reported outcome in subjects treated medically for acute pancreatitis: a follow-up study.Everolimus in Pancreatic Neuroendocrine Carcinomas G3.68Ga DOTANOC PET/CT detects primary malignant insulinoma.68Ga-DOTA-NOC PET/CT detects somatostatin receptors expression in von hippel-lindau cerebellar disease.(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours.Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
P50
Q33417013-339129F4-BE62-4185-A058-7868DDC73CFBQ34073712-3BB04F4A-79BC-4FC9-A31F-B232958CB061Q35598674-5979AF8A-0D90-410F-8374-FDE2134A8BF2Q36090395-9F949BB3-0AE7-4468-AC85-08818DEB9868Q37350299-2BCD8A8A-3185-4653-9235-FC3B2A79C64AQ37402462-0306026D-4234-4535-919E-3310A76B71B0Q37783669-31A3A4F4-2020-49CB-8B18-04D2410A20A8Q37990397-7AD6F8F8-6F45-4DD1-A66F-FA084A3370ACQ38691825-4CC4032D-FB6E-485F-9E08-D0490AE3EA87Q40503265-EC3BFB16-64AA-47BE-92EC-7A562C289EC5Q41152322-3D57AC5C-F708-42BB-AFE1-B5809C654FE3Q41378482-3421BAA6-F93B-4838-954E-4BB31D5DBDD9Q42523470-CF7CDAA7-03F8-4290-A0C5-EC8DBA9C174AQ43270685-8417F92B-4F26-4A08-87AF-725EC31B0DD4Q43434366-740BAE48-7FE7-4AC6-80DE-427B39F2994DQ43618813-E60C9026-4D73-4425-A88B-C47C55921947Q44268970-885EFED9-64EA-4AE2-ACA7-DE6D62403E2CQ44419599-BBA61339-8338-4524-A151-5F9FBAAC2002Q44646733-F8F06DA6-FC27-48CC-BB34-BC3DC6C95257Q44725924-BCE45A55-8883-4197-9383-A4FECA2EB3ADQ45126334-A2DF7F7A-82AA-40DF-8965-26384A7A9660Q45862395-2F46A428-759A-4F95-B0B8-3920245B43D1Q45890813-42410A14-1C00-42FD-B1B3-F5D9F85C2283Q46152235-9C857E66-AD88-436C-B588-F33225622B72Q46725898-72A8481B-DAFC-4542-9264-29BEB001DF5BQ46852916-C1C657D8-A9C8-4FA3-AD78-1D6AB23CCBD3Q47864375-D2DC87CB-C01D-489E-B778-C624B239184AQ48009649-B2579FFD-D577-4228-A19D-75478B74A026Q48278842-49600BAE-EE66-45EE-AC31-EE1AF1F74F24Q50787558-39443487-E420-44D4-B5E3-39D40D5FF726Q51053000-8B514F50-9ACD-468D-AB05-4253421156D1Q51702092-0ED63990-D33A-468A-AC2C-B5C0751D5833Q51747280-2D760035-0E48-4666-9756-24798C87E130Q51868194-14BD33D5-CFD6-4A2F-A165-045F436A120FQ51869057-62058E56-C0CB-41A7-AADD-41F61E81401BQ52925319-4742BEFE-CA8B-42E4-951D-0AA45FFB7FDBQ53065988-03FDFBA9-1182-4091-9902-316AC2AB8B2BQ53255322-D68805DD-9847-472B-BB3E-21EF663B742FQ53312438-C56BA793-F0F2-4F7A-9623-3E7A7F8D1696Q53485156-AA6C6028-2CD2-45E9-98B4-704538BF0F77
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Davide Campana
@ast
Davide Campana
@en
Davide Campana
@es
Davide Campana
@nl
Davide Campana
@sl
type
label
Davide Campana
@ast
Davide Campana
@en
Davide Campana
@es
Davide Campana
@nl
Davide Campana
@sl
prefLabel
Davide Campana
@ast
Davide Campana
@en
Davide Campana
@es
Davide Campana
@nl
Davide Campana
@sl
P1053
D-3988-2014
P106
P21
P31
P3829
P496
0000-0002-4615-7340